Pharmaceutical Research Veteran Joins Ipsos

New York, NY - Ipsos today appointed James B. (Jim) Douglass to lead its North American Health Division, which specializes in conducting both custom and syndicated physician, patient, and animal health research. Douglass joins the company with over 10 years of senior executive experience. Prior to joining Ipsos, he was the General Manager of Information Services and CIO of IMPATH, Inc., a cancer information company. Douglass has also been the proprietor of Douglass Associates, a consulting practice providing services to sales and marketing organizations within the pharmaceutical industry, and held General Manager positions with both NDC Health and IMS America (now IMS Health). In his new position as Senior Vice President and General Manager, Douglass will develop Ipsos' expertise in the health industry in North America as well as lead a specialized team dedicated to bringing insights to clients in the pharmaceutical industry. He currently works out of Ipsos' headquarters in New York, but will be moving to the company's new Parsippany, New Jersey office when it opens in December this year. The Health Division is part of Ipsos-Insight, the company's marketing research flagship. "Jim's extensive background and proven skills as a leader and senior executive make him eminently qualified to serve as Senior Vice President and General Manager of our growing Health division," said Tom Neri, President of Ipsos-Insight Services, Health & Technology and Ipsos Loyalty in the U.S. "He joins the company with a proven record of expanding business opportunities, developing innovative strategies, and a wealth of experience in the health care industry." Douglass holds both a master's degree and a doctorate in applied statistics and research design from Michigan State University, and a BA in mathematics, also from Michigan State University. "This represents a unique opportunity to be a part of a customer-oriented and dedicated service within one of the few truly global survey-based market research organizations," Douglass said. "It's exciting to be a part of a division which has carved out a strong industry niche based on deep product and therapeutic knowledge combined with global research capabilities. When you factor in the expertise and reach of other Ipsos member companies, we believe Ipsos can be one of the top Health and Pharmaceutical research providers in the world." For more information on this release, please contact: Jim Douglass Senior Vice President & General Manager Ipsos-Insight, Health Division 212.265.3200 About Ipsos-Insight Ipsos-Insight, the flagship marketing research division of Ipsos in the U.S., has industry specialists serving companies in the following categories: consumer products; technology and communications; health and pharmaceutical; financial services; cable, media and entertainment; agrifood; energy and utilities; and lottery and gaming. Ipsos-Insight provides custom and tracking research services to domestic clients, as well as U.S.-based multinationals. It offers concept and product testing, package testing, attitude and usage studies, omnibuses, tracking systems, brand equity, price optimization and segmentation, marketing models, advanced analytics, and global research. Ipsos-Insight is an Ipsos company, a leading global survey-based market research group. To learn more, visit: www.ipsos-insight.com. About Ipsos Ipsos is a leading global survey-based market research group, with revenues of $644 million in 2003. It offers a full suite of research services, guided by industry experts and bolstered by advanced analytics and methodologies in advertising, marketing, public opinion and customer loyalty research, as well as forecasting and modeling. Member companies also offer a full line of custom, syndicated, omnibus, panel, and online research products and services. To learn more, visit: www.ipsos.com. Ipsos is listed on the Euronext Paris Premier Marchй, and is part of the SBF 120 and Next Prime Indices as well as eligible to the Deferred Settlement System (SRD). Euroclear code 7329, Reuters ISOS.LN, Bloomberg IPS FP